Trial Search Results

Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

This phase I trial will assess primarily the safety and secondarily anti-inflammatory effect of Episcleral Dexamethasone in patients suffering from macular edema and other disorders of the retina, choroid and vitreous.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Targeted Therapy Technologies, LLC

Stanford Investigator(s):


  • Drug: Episcleral Dexamethasone


Phase 1


Inclusion Criteria:

   - Age >= 18 years;

   - Visual acuity letter score in study eye < 70 and ≥ 25 letters (approximate Snellen
   equivalent 20/32 to 20/320);

   - Ophthalmoscopic evidence of center-involved macular edema, within the central subfield

   - Inflammatory disorders of the sclera, choroid, retina or vitreous

Exclusion Criteria:

   - Inability to understand informed consent, cooperate with testing or return to follow
   up visits;

   - Pregnant or lactating women;

   - Co-existent ocular disorder of the cornea, lens or media that will interfere with
   assessment of safety or efficacy.

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Amy Dennis, RN